哮喘中的抗IgE治疗：半乳糖凝集素-3作为预测标志物 - Suppr

Suppr

超能文献

Anti-IgE treatment in asthma: galectin-3 as a predictive marker.

作者信息

Moretta Lorenzo, Pistoia Vito

机构信息

Istituto Giannna Gaslini, Genova, Italy.

出版信息

Immunol Lett. 2014 Nov;162(1 Pt A):1. doi: 10.1016/j.imlet.2014.09.012. Epub 2014 Sep 18.

DOI:10.1016/j.imlet.2014.09.012

PMID:25241018

Abstract

摘要

相似文献

Anti-IgE treatment in asthma: galectin-3 as a predictive marker.

Immunol Lett. 2014 Nov;162(1 Pt A):1. doi: 10.1016/j.imlet.2014.09.012. Epub 2014 Sep 18.

[New insight into the airway remodeling of asthma:IgE].

Zhonghua Jie He He Hu Xi Za Zhi. 2013 May;36(5):367-70.

Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases.

Allergy. 2004 Jul;59(7):698-700. doi: 10.1111/j.1398-9995.2004.00548.x.

[Dermatological implications of omalizumab, an anti-IgE antibody].

Rev Med Suisse. 2015 Apr 1;11(468):779-80, 782-3.

[Pneumology. Anti-IgE antibodies in the treatment of asthma].

Rev Med Suisse. 2007 Jan 10;3(93):56-9.

[Research progress in the application of anti-IgE antibody for allergic asthma in school-age children].

Zhonghua Er Ke Za Zhi. 2020 Mar 2;58(3):255-258. doi: 10.3760/cma.j.issn.0578-1310.2020.03.023.

[Anti-IgE therapy].

Pneumonol Alergol Pol. 2002;70 Suppl 1:76-81.

The role of anti-IgE in managing difficult-to-treat or severe asthma.

Prof Nurse. 2001 Oct;17(2):118-20.

[Anti-IGE therapy in asthma].

Tunis Med. 2002 Oct;80(10):575-80.

Omalizumab in asthma: an update on recent developments.

J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):525-36.e1. doi: 10.1016/j.jaip.2014.03.010. Epub 2014 Jun 11.

引用本文的文献

Plasma Galectin-3 and urine proteomics predict FEV improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study.

World Allergy Organ J. 2020 Jan 24;13(1):100095. doi: 10.1016/j.waojou.2019.100095. eCollection 2020 Jan.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Anti-IgE treatment in asthma: galectin-3 as a predictive marker.

Immunol Lett. 2014 Nov;162(1 Pt A):1. doi: 10.1016/j.imlet.2014.09.012. Epub 2014 Sep 18.

[New insight into the airway remodeling of asthma:IgE].

Zhonghua Jie He He Hu Xi Za Zhi. 2013 May;36(5):367-70.

Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases.

Allergy. 2004 Jul;59(7):698-700. doi: 10.1111/j.1398-9995.2004.00548.x.

[Dermatological implications of omalizumab, an anti-IgE antibody].

Rev Med Suisse. 2015 Apr 1;11(468):779-80, 782-3.

[Pneumology. Anti-IgE antibodies in the treatment of asthma].

Rev Med Suisse. 2007 Jan 10;3(93):56-9.

[Research progress in the application of anti-IgE antibody for allergic asthma in school-age children].

Zhonghua Er Ke Za Zhi. 2020 Mar 2;58(3):255-258. doi: 10.3760/cma.j.issn.0578-1310.2020.03.023.

[Anti-IgE therapy].

Pneumonol Alergol Pol. 2002;70 Suppl 1:76-81.

The role of anti-IgE in managing difficult-to-treat or severe asthma.

Prof Nurse. 2001 Oct;17(2):118-20.

[Anti-IGE therapy in asthma].

Tunis Med. 2002 Oct;80(10):575-80.

Omalizumab in asthma: an update on recent developments.

J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):525-36.e1. doi: 10.1016/j.jaip.2014.03.010. Epub 2014 Jun 11.

引用本文的文献

Plasma Galectin-3 and urine proteomics predict FEV improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study.

World Allergy Organ J. 2020 Jan 24;13(1):100095. doi: 10.1016/j.waojou.2019.100095. eCollection 2020 Jan.